Fiona joined Novartis in 2012 and has spent the last six years in Market Access (MAx). The UK environment provides the challenges and opportunities that allow Fiona to work creatively and innovatively to find new ways to enable patients to have uninhibited (on label) access to medicines, currently developing New Commercial Models across the portfolio. In fact, it’s something personal to the whole MAx team who are all passionately innovating to optimise access for patients.

Since October 2023, as NHS England’s Director of Medicines Value and Access (MVA), Fiona has leveraged the health service’s considerable clinical and commercial expertise to ensure that patients across the country benefit from innovative and everyday medicines at cost-effective prices to deliver value for taxpayers from a £20bn annual medicines budget. Over the past year Fiona has been focused on ensuring that the NHS is aligning its commercial approach to medicines at every level, capitalising on national ‘do once’ opportunities and the capabilities of local systems to improve the outcomes of the populations they serve.

Fiona was appointed NHS England’s interim Chief Commercial Officer (CCO) in December 2024. As interim CCO, Fiona has accountabilities across the central commercial function, commercial delivery and governance and commercial operations, in addition to responsibility for Supply Chain Coordination Limited.

Prior to joining NHS England, Fiona built a career in the pharmaceutical industry, holding senior commercial, marketing and value and access roles at multinational companies that partnered with the NHS and health systems around the World.